RxDoctor Payments Data

Mark Schaar, MD

Family Medicine · Lansing, MINPI 1932180148

Payments from drug & device makers

$16,362in general payments, 2019–2025

Across 943 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • GSK$1K
  • Amgen$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Pfizer$919
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$16,25499%
  • Education$1081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)126$1,999
Novo Nordisk160$1,612
GSK65$1,379
Amgen73$1,218
Otsuka America Pharmaceutical, Inc.48$1,090
Pfizer50$919
AstraZeneca22$886
Lilly USA, LLC67$677
Axsome Therapeutics, Inc.16$617
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)13$400
Merck28$365
Teva Pharmaceuticals USA, Inc.23$333
Johnson & Johnson14$288
Biohaven Pharmaceuticals, Inc.7$281
Nestle Healthcare Nutrition Inc.12$254
Astellas Pharma US Inc12$243
Antares Pharma, Inc.14$235
Bayer5$231
Vanda Pharmaceuticals Inc.10$230
Gilead15$214
Amarin Pharma, Inc.13$209
Novartis14$202
Radius Health, Inc.9$176
Esperion Therapeutics, Inc.4$174
Grifols USA, LLC4$171
Biohaven Pharmaceutical Holding Company Ltd.8$162
Boehringer Ingelheim10$161
Eisai Inc.4$136
Paratek Pharmaceuticals, Inc.8$125
Takeda Pharmaceuticals U.S.A., Inc.10$123
Exact Sciences4$87
Mylan Specialty L.p.5$81
Lundbeck LLC5$79
Jazz Pharmaceuticals Inc.5$68
GRT US Holding, Inc.5$68
Seqirus USA Inc4$68
Abbott3$64
Sanofi Pasteur Inc.4$63
Xeris Pharmaceuticals, Inc.3$62
Boston Scientific3$60
Alkermes, Inc.2$54
Sanofi-aventis U.S. LLC3$46
Averitas Pharma Inc.3$42
Otsuka Pharmaceutical Development & Commercialization, Inc.2$41
Electromed, Inc.4$35
Halozyme Inc2$34
Abiomed2$32
Collegium Pharmaceutical, Inc.2$30
E.r. Squibb & Sons, L.L.C.2$29
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$28
Actelion Pharmaceuticals US, Inc.1$20
Viiv Healthcare Company1$17
Phathom Pharmaceuticals, Inc.1$17
Idorsia Pharmaceuticals US Inc1$16
Aimmune Therapeutics, Inc.1$16
Insmed, Inc.1$16
Sunovion Pharmaceuticals Inc.1$14
Upsher-smith Laboratories LLC1$13
Daiichi Sankyo Inc.1$12
Dynavax Technologies Corporation1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,362 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$40,532
Medicare patients
103
Services billed
735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$97,741
JardianceEmpagliflozin75$81,692
XareltoRivaroxaban61$71,238
EliquisApixaban52$53,672
JanuviaSitagliptin Phosphate37$46,270
FarxigaDapagliflozin Propanediol68$42,355
TrulicityDulaglutide33$30,340
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$24,742
RexultiBrexpiprazole14$19,901
MyrbetriqMirabegron27$19,418
EntrestoSacubitril/Valsartan18$18,044
Janumet XrSitagliptin Phos/Metformin Hcl12$17,097
TradjentaLinagliptin23$15,529
MounjaroTirzepatide13$12,578
Spiriva RespimatTiotropium Bromide13$10,639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$161$107,859111 claims
Novo NordiskOzempic$1,612$97,74170 claims
Johnson & JohnsonXarelto$288$71,23861 claims
MerckJanuvia, Janumet Xr$365$63,36849 claims
PfizerEliquis$919$53,67252 claims
Lilly USA, LLCTrulicity, Mounjaro$677$42,91746 claims
AstraZenecaFarxiga$886$42,35568 claims
GSKTrelegy Ellipta$1,379$24,74221 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,090$19,90114 claims
Astellas Pharma US IncMyrbetriq$243$19,41827 claims
NovartisEntresto$202$18,04418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →